â– LECTURE OVERVIEW: Kawasaki Disease is an acute, self-limiting medium-vessel necrotizing vasculitis that primarily affects infants and toddlers.
â– SPECIFIC TOXIC CHANNELS:
1. Endothelial Inflammation: Characterized by segment-like inflammation of muscular medium arteries, particularly coronary arteries.
2. Clinical Diagnoses: Requires high fever lasting over 5 days, plus at least 4 of 5 CRASH symptoms:
- C - Conjunctivitis (bilateral, non-purulent, sparing the limbus).
- R - Rash (polymorphous, erythematous).
- A - Adenopathy (cervical, unilateral, node >1.5 cm).
- S - Strawberry tongue (erythematous, with cracked red lips).
- H - Hand/foot swelling initially, with desquamation of skin under nails in recovery.
â– THERAPEUTIC TARGETS & MANAGEMENT:
Primary pharmacological intervention aims to restore physiological homeostatic balance. This is achieved by either competitively blocking receptor sites, allosterically inhibiting enzymes, or supplementing missing metabolic products.
â– PHARMACODYNAMIC TARGET ENGAGEMENT:
Receptor binding dynamics dictate the overall speed, duration, and magnitude of physiological responses to therapeutic agents.
[HY-BOARD-1364]
🌟 Dynamic Clinical Key:
Carries a high risk of developing coronary artery aneurysms in up to 25% of untreated cases. Crucially, Kawasaki disease is the only clinical condition where Aspirin (which is otherwise contraindicated in children due to Reye's syndrome) is administered, alongside intravenous immunoglobulin (IVIG). Absolute contraindications include pregnancy, renal insufficiency, or concurrent use of metabolic inhibitors. Watch closely for ligand-receptor saturation effects and subsequent tolerance or resistance.